$7.30
▲ +$0.16
(+2.24%)
Vol 14.1M
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$2.0B
ROE
-193.3%
Margin
-422.3%
D/E
0.00
Beta
-0.01
52W
$2–$4
Wall Street Consensus
11 analysts · Apr 20264
Strong Buy
6
Buy
1
Hold
0
Sell
0
Strong Sell
90.9%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 75.0%
Next Report
May 11, 2026
EPS Estimate: $-0.07
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.07 | — | — |
| Dec 2025 | $-0.10 | $-0.06 | +$0.04 |
| Sep 2025 | $-0.11 | $-0.07 | +$0.04 |
| Jun 2025 | $-0.11 | $-0.10 | +$0.01 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $7.6M | $16.5M | $26.4M | $32.1M | $38.3M |
| Net Income | — | -$59.2M | -$129.6M | -$92.6M | -$67.3M | -$61.9M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -193.3% | -193.3% | -193.3% | -193.3% | -193.3% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -350.3% | -648.6% | -648.6% | -648.6% | -422.3% | -422.3% |
| Gross Margin | 99.5% | — | — | — | 99.5% | 99.5% |
| D/E Ratio | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 4.11 | 4.11 | 4.11 | 4.11 | 5.77 | 5.77 |
Key Ratios
ROA (TTM)
-86.7%
P/S (TTM)
23.62
P/B
3.1
EPS (TTM)
$-0.41
CF/Share
$-1.09
Rev Growth 3Y
+151.2%
52W High
$4.27
52W Low
$1.83
$1.83
52-Week Range
$4.27
Financial Health
Free Cash Flow
-$71.7M
Net Debt
$429.7M
Cash
$88.3M
Total Debt
$518.1M
As of Dec 31, 2025
How does IBRX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
IBRX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
23.6
▲
84%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
3.1
▲
26%
above
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
IBRX profitability vs Biotechnology peers
ROE
-193.3%
▼
187%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-422.3%
▼
47%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
99.6%
▲
27%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-86.7%
▼
86%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
IBRX financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
5.8
▲
30%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
0.0
▼
101%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
IBRX fundamentals radar
IBRX
Peer median
Industry
IBRX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
IBRX vs peers: key metrics
Latest News
ImmunityBio Inc. (IBRX) Announces Approval for ANKTIVA® in Macau SAR, China
Yahoo Finance · Mar 25
ImmunityBio (IBRX) Announces NCCN Update Clinical Practice Guidelines to Include ANKTIVA for …
Yahoo Finance · Mar 25
Stock Market Today, March 24: Oil, AI, and Private Credit Fears Weigh …
Nasdaq · Mar 24
Why ImmunityBio Stock Is Down More Than 20% Today
Yahoo Finance · Mar 24
Jim Cramer on ImmunityBio: “That Stock Is Part of the Magical Thinking …
Yahoo Finance · Mar 21